ARS Pharmaceuticals, Inc. (SPRY) Research

ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.

Market snapshot

Symbol
SPRY
Price
$9.65
Day change
-2.53%
Market cap
$958.3M
P/E ratio
-4.84x
52-week range
6.66-18.9
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$25.50

Recent news

  • ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

    ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) will release earnings for its first quarter before the opening bell on Friday, May 15.

Peer companies

  • Arbutus Biopharma Corporation (ABUS)
  • GH Research PLC (GHRS)
  • Kura Oncology, Inc. (KURA)
  • LENZ Therapeutics, Inc. (LENZ)
  • Nanobiotix S.A. (NBTX)
  • ProKidney Corp. (PROK)
  • Palvella Therapeutics, Inc. (PVLA)
  • Rezolute, Inc. (RZLT)

Recent insider activity

  • Karas Eric — M-Exempt (25000 shares) on 2026-06-12
  • Karas Eric — M-Exempt (25000 shares) on 2026-06-12
  • Karas Eric — S-Sale (25000 shares) on 2026-06-12
  • Fitzpatrick Alexander A — S-Sale (3355 shares) on 2026-06-12
  • Casale Donn — trade (0 shares) on 2026-06-01

Open ARS Pharmaceuticals, Inc. (SPRY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.